Description of Research Expertise:
The Circulating Tumor Material (CTM) Center, led by Director Dr. Erica Carpenter, focuses on the identification, capture, and analysis of Circulating Tumor Cells (CTCs) and cell-free DNA (cfDNA) from cancer patients. Blood, bone marrow, pleural effusions, and other non-invasively captured patient samples are used to detect biomarkers which allow: 1) early detection of disease as well as post-therapy monitoring of minimal residual disease, 2) an efficient means of determining clinical and biological response to therapy and, thus, clinical decision making, and, 3) cancer genetic phenotyping to drive personalized medicine that obviates the need for serial biopsies in a population of patients for which these procedures are difficult, risky, and insufficient. The focus of the CTM Center is driven by the needs of clinicians and translational investigators, and realized through collaborative work with investigators in the Penn School of Medicine, the Penn School of Engineering, and the Center for Personalized Diagnostics. Moreover, when it is determined that outsourcing of technology development is preferable, collaborative efforts with industry partners are actively sought, and these efforts have already been initiated in focused areas.
Michael J. LaRiviere, MD, Bardia Yousefi, PhD, Austin L. Chien, BA, José Marcio Luna PhD, Sharyn I.Katz, MD, MTR, Michelle Hershman, MD, Leonid Roshkovan, MD, Maya Galperin-Aizenberg, MD, Charu Aggarwal MD, MPH, Erica L. Carpenter PhD, MBA, Despina Kontos PhD, Jeffrey C. Thompson MD, MTR: Radiomic phenotypes associated with non-small cell lung cancer EGFR mutational
profile and therapy response to EGFR inhibitors Radiological Society of North America : 2019.
Bardia Yousefi, PhD, Michael LaRiviere, MD, Leonid Roshkovan, MD, Michelle Hershman, MD, Austin L., Chien, BA, Yogesh Gupta, DO, Maya Galperin-Aizenberg, MD, José Marcio Luna, PhD, Jeffrey C. Thompson MD, MTR, Charu Aggarwal PhD, MPH, Erica L. Carpenter MBA, PhD, Despina Kontos PhD, Sharyn I. Katz MD, MTR: Radiomic biomarker-predicted response to combination chemo-immunotherapy for
non-small cell lung cancer Radiological Society of North America : 2019.
L Roshkovan; B Yousefi; M J LaRiviere, MD; M L Hershman, MD; M Galperin-Aizenberg, MD; J M Luna Castaneda, J Thompson, MD; C Aggarwal, MD; E Carpenter, PhD; D Kontos, PhD; Sharyn Katz, MD: Impact of intravenous contrast enhancement on predictive radiomic features in patients with NSCLC treated with proton therapy.Impact of intravenous contrast enhancement on predictive radiomic features in patients with lung cancer Radiological Society of North America Annual Meeting : 2019.
Jacob E. Till,Taylor A. Black,Caren Gentile,Jacquelyn J. Roth,Robyn Sussman,Jazmine Mays,Zhuoyang Wang,Hareena Kaur,Renee Chang,Stephanie S. Yee,Kojo Elenitoba-Johnson,Erica L. Carpenter
: Measuring yield and variation: Evaluation of plasma circulating cell-free DNA extraction and measurement methods Association for Molecular Pathology Annual Meeting & Expo : 2019.
B Yousefi; M J LaRiviere, MD; A Chien; J M Luna Castaneda; S I Katz, MD; M L Hershman; Roshkovan L; Galperin-Aizenberg M, Aggarwal C; Carpenter E; Kontos D; Thompson J: Radiomic phenotypes associated with non-small cell lung cancer EGFR mutational profile and therapy response to EGFR inhibitors. Pendergrass Symposium, Perelman School of Medicine at the University of Pennsylvania : 2019.
Charu Aggarwal1, Jeffrey C Thompson1, Austin Chien1, Katie Quinn2, Martina Lefterova2, Rebecca Nagy2, Stephanie Yee1, Christine A. Ciunci1, Evan W. Alley1, , Joshua M. Bauml1, Roger B. Cohen1, Corey J. Langer1, Erica L. Carpenter1: Dynamic monitoring of circulating tumor DNA next-generation gene sequencing as a predictivebiomarker of response and progression free survival after pembrolizumab monotherapy in patients with advanced NSCLC
American Society of Clinical Oncologists, General Meeting : 2019.
M J LaRiviere; B Yousefi; L Roshkovan; M L Hershman; A Chien; Y S Gupta, M Galperin-Aizenberg, J L Castaneda; C Aggarwal; E L Carpenter; D Kontos; J Thompson; S Katz: Radiomic biomarker-predicted response to combination chemo-immunotherapy for non-small cell lung cancer Pendergrass Symposium, Perelman School of Medicine at the University of Pennsylvania : 2019.
Moen Sen, Friedrich Hahn, Taylor A. Black, Maureen DeMarshall, Warren, Porter, Eileen Snowden, Stephanie S. Yee, Frances Tong, Mitchell Ferguson, Emylee N. Fleshman1, Hiroshi Nakagawa3, Gary W. Falk3, Gregory G. Ginsberg, Michael L. Kochman, Rainer Blaesius, Anil K. Rustgi and Erica L. Carpenter: Flow based single cell analysis of the immune landscape distinguishes Barrett's esophagus from adjacent normal tissue Oncotarget : 2019.
Kim Anna Reiss, Rosemarie Mick, Mark H. O'Hara, Ursina R. Teitelbaum, Thomas Benjamin Karasic, Charles John Schneider, Peter J. O'Dwyer, Danielle Karlson, Stacy Cowden, Mary Jane Fuhrer, Erica Carpenter, Austin A Pantel, Mehran Makvandi, David A. Mankoff, Katharine Nathanson, Kara Noelle Maxwell, Gregory Lawrence Beatty, Susan M. Domchek: A Randomized Phase II Trial of Niraparib Plus Either Nivolumab or Ipilimumab in Patients With Advanced Pancreatic Cancer Whose Cancer Has Not Progressed on Platinum-Based Therapy
American Society of Clinical Oncologists General Meeting : 2019.
Mark H. O’Hara, Eileen O’Reilly, Rosemarie Mick, Gauri Varadhachary, Zev Wainberg, Andrew Ko, George Fisher, Osama Rahma, Jaclyn P. Lyman, Christopher R. Cabanski, Erica L. Carpenter, Travis Hollmann, Pier F. Gherardini, Lacey Kitch, Cheryl Selinsky, Theresa LaVallee, Ovid C. Trifan, Ute Dugan, Vanessa Lucey, Robert H. Vonderheide: A Phase 1b Study of CD40 Agonistic Monoclonal Antibody APX005M Together with Gemcitabine (Gem) and nab-Paclitaxel (NP) with or without Nivolumab (Nivo) in Untreated Metastatic Ductal Pancreatic Adenocarcinoma (PDAC) Patients American Association of Cancer Research General Meeting : 2019.